Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 outpatients meta-analysis

TOGETHER, 2021
 
NCT04727424
RCTfluvoxamineplaceboCOVID 19 outpatientssome concern
741/756 suggested
  • suggested 36 % decrease in emergency room observation for > 6 hours or hospitalization (PE) with a moderate degree of certainty due to some concern in risk of bias
Lenze (STOP COVID 1), 2020
 
NCT04342663
RCTfluvoxamineplaceboCOVID 19 outpatientssome concern
80/72 conclusif
  • demonstrated 93 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
1 study excluded by filtering options (1 RCT / 0 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).